rg3487
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00454870)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Serotonin 3 (5-HT3) receptorANTAGONIST
Serotonin 3 (5-HT3) receptor antagonist
- Neuronal acetylcholine receptor protein alpha-7 subunitPARTIAL AGONIST
CHRNA7 partial agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544952 ↗
Also known as
- mem 3454
- mem 3454
- mem-3454
- mem-3454
- n-((3s)-1-azabicyclo(2.2.2)oct-3-yl)-1h-indazole-3-carboxamide hydrochloride
- rg3487
- rg3487
- rg3487
- rg-3487
- rg-3487
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00725855 | Phase 2 | Aug 1, 2008 | Memory Pharmaceuticals, Roche, University of Colorado, Denver |
| NCT00604760 | Phase 2 | Dec 1, 2007 | Memory Pharmaceuticals |
| NCT00454870 | Phase 2 | Feb 1, 2007 | Memory Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Memory Pharmaceuticals | For profit | 3 | 3 | 1 | 2007 |
| Roche | For profit | 1 | 0 | 1 | 2008 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2008 |
3 organizations
Page 1 / 1